<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39376569</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Distinct soluble immune checkpoint profiles characterize COVID-19 severity, mortality and SARS-CoV-2 variant infections.</ArticleTitle><Pagination><StartPage>1464480</StartPage><MedlinePgn>1464480</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1464480</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1464480</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Over the past four years, the COVID-19 pandemic has posed serious global health challenges. The severe form of disease and death resulted from the failure of immune regulatory mechanisms, closely highlighted by the dual proinflammatory cytokine and soluble immune checkpoint (sICP) storm. Identifying the individual factors impacting on disease severity, evolution and outcome, as well as any additional interconnections, have become of high scientific interest.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, we evaluated a novel panel composed of ten sICPs for the predictive values of COVID-19 disease severity, mortality and Delta vs. Omicron variant infections in relation to hyperinflammatory biomarkers. The serum levels of sICPs from confirmed SARS-CoV-2 infected patients at hospital admission were determined by Luminex, and artificial neural network analysis was applied for defining the distinct patterns of molecular associations with each form of disease: mild, moderate, and severe.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Notably, distinct sICP profiles characterized various stages of disease and Delta infections: while sCD40 played a central role in all defined diagrams, the differences emerged from the distribution levels of four molecules recently found and relatively less investigated (sCD30, s4-1BB, sTIM-1, sB7-H3), and their associations with various hematological and biochemical inflammatory biomarkers. The artificial neural network analysis revealed the prominent role of serum sTIM-1 and Galectin-9 levels at hospital admission in discriminating between survivors and non-survivors, as well as the role of specific anti-interleukin therapy (Tocilizumab, Anakinra) in improving survival for patients with initially high sTIM-1 levels. Furthermore, strong associations between sCD40 and Galectin-9 with suPAR defined the Omicron variant infections, while the positive match of sCD40 with sTREM-1 serum levels characterized the Delta-infected patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Of importance, this study provides a comprehensive analysis of circulatory immune factors governing the COVID-19 pathology, and identifies key roles of sCD40, sTIM-1, and Galectin-9 in predicting mortality.</AbstractText><CopyrightInformation>Copyright Â© 2024 Paranga, Pavel-Tanasa, Constantinescu, Iftimi, Plesca, Miftode, Cianga and Miftode.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paranga</LastName><ForeName>Tudorita Gabriela</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavel-Tanasa</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Immunology, St. Spiridon County Clinical Emergency Hospital, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Immunology, St. Spiridon County Clinical Emergency Hospital, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iftimi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plesca</LastName><ForeName>Claudia Elena</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miftode</LastName><ForeName>Ionela-Larisa</ForeName><Initials>IL</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cianga</LastName><ForeName>Petru</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Immunology, St. Spiridon County Clinical Emergency Hospital, Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miftode</LastName><ForeName>Egidia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases (Internal Medicine II), Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Parascheva Clinical Hospital for Infectious Diseases, Iasi, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082102">Immune Checkpoint Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082102" MajorTopicYN="N">Immune Checkpoint Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">STIM-1</Keyword><Keyword MajorTopicYN="N">galectin-9</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">neural network</Keyword><Keyword MajorTopicYN="N">sCD40</Keyword><Keyword MajorTopicYN="N">soluble immune checkpoints</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376569</ArticleId><ArticleId IdType="pmc">PMC11456479</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1464480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. (2020) 8:420â2. doi:Â 10.1016/S2213-2600(20)30076-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. (2020) 395:1014â5. doi:Â 10.1016/S0140-6736(20)30633-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30633-4</ArticleId><ArticleId IdType="pmc">PMC7138151</ArticleId><ArticleId IdType="pubmed">32197108</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranga TG, Pavel-Tanasa M, Constantinescu D, Plesca CE, Petrovici C, Miftode IL, et al. . Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants. Front Immunol. (2023) 14:1213246. doi:Â 10.3389/fimmu.2023.1213246</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1213246</ArticleId><ArticleId IdType="pmc">PMC10302717</ArticleId><ArticleId IdType="pubmed">37388734</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Rabaan AA, Alwarthan S, Alhajri M, Halwani MA, Alshengeti A, et al. . Regulatory T cells (Tregs) and COVID-19: unveiling the mechanisms, and therapeutic potentialities with a special focus on long COVID. Vaccines (Basel). (2023) 11:699. doi:Â 10.3390/vaccines11030699</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030699</ArticleId><ArticleId IdType="pmc">PMC10059134</ArticleId><ArticleId IdType="pubmed">36992283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. . Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. (2020) 369:eabc8511. doi:Â 10.1126/science.abc8511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau-Exposito J, Sanchez-Gaona N, Massana N, Suppi M, Astorga-Gamaza A, Perea D, et al. . Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat Commun. (2021) 12:3010. doi:Â 10.1038/s41467-021-23333-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23333-3</ArticleId><ArticleId IdType="pmc">PMC8140108</ArticleId><ArticleId IdType="pubmed">34021148</ArticleId></ArticleIdList></Reference><Reference><Citation>Maison DP, Deng Y, Gerschenson M. SARS-CoV-2 and the host-immune response. Front Immunol. (2023) 14:1195871. doi:Â 10.3389/fimmu.2023.1195871</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1195871</ArticleId><ArticleId IdType="pmc">PMC10315470</ArticleId><ArticleId IdType="pubmed">37404823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. (2020) 183:158â68.e14. doi:Â 10.1016/j.cell.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Salvati L, Maggi L, Capone M, Vanni A, Spinicci M, et al. . Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. (2020) 130:4694â703. doi:Â 10.1172/JCI138554</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138554</ArticleId><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. . Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. (2020) 17:533â5. doi:Â 10.1038/s41423-020-0402-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0402-2</ArticleId><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann J, Prezzemolo T, Vanderbeke L, Roca CP, Gerbaux M, Janssens S, et al. . Humblet-Baron: Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. Clin Transl Immunol. (2020) 9:e1204. doi:Â 10.1002/cti2.1204</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1204</ArticleId><ArticleId IdType="pmc">PMC7662088</ArticleId><ArticleId IdType="pubmed">33209300</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvan-Pena S, Leon J, Chowdhary K, Michelson DA, Vijaykumar B, Yang L, et al. . Profound Treg perturbations correlate with COVID-19 severity. Proc Natl Acad Sci U S A. (2021) 118:e2111315118. doi:Â 10.1073/pnas.2111315118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111315118</ArticleId><ArticleId IdType="pmc">PMC8449354</ArticleId><ArticleId IdType="pubmed">34433692</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam H, Koh JY, Jung JH, Jeong H, Jeong HW, Cheon S, et al. . Distinctive dynamics and functions of the CD4+CD25+FOXP3+ Regulatory T cell population in patients with severe and mild COVID-19. J Immunol. (2023) 210:1687â99. doi:Â 10.4049/jimmunol.2200290</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2200290</ArticleId><ArticleId IdType="pubmed">37042681</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. (2013) 13:227â42. doi:Â 10.1038/nri3405</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3405</ArticleId><ArticleId IdType="pmc">PMC3786574</ArticleId><ArticleId IdType="pubmed">23470321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery. (2018) 8:1069â86. doi:Â 10.1158/2159-8290.CD-18-0367</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-18-0367</ArticleId><ArticleId IdType="pubmed">30115704</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J, Li Y. Immune checkpoint alterations and their blockade in COVID-19 patients. Blood Sci. (2022) 4:192â8. doi:Â 10.1097/BS9.0000000000000132</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BS9.0000000000000132</ArticleId><ArticleId IdType="pmc">PMC9592141</ArticleId><ArticleId IdType="pubmed">36311817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Y, Wang Y, Wu X, Han J, Li G, Hua M, et al. . Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. (2020) 5:192. doi:Â 10.1038/s41392-020-00308-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00308-2</ArticleId><ArticleId IdType="pmc">PMC7475713</ArticleId><ArticleId IdType="pubmed">32895366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu D, Ao X, Yang Y, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. (2018) 6:132. doi:Â 10.1186/s40425-018-0449-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-018-0449-0</ArticleId><ArticleId IdType="pmc">PMC6260693</ArticleId><ArticleId IdType="pubmed">30482248</ArticleId></ArticleIdList></Reference><Reference><Citation>Avendano-Ortiz J, Lozano-Rodriguez R, Martin-Quiros A, Terron V, Maroun-Eid C, Montalban-Hernandez K, et al. . The immune checkpoints storm in COVID-19: Role as severity markers at emergency department admission. Clin Transl Med. (2021) 11:e573. doi:Â 10.1002/ctm2.573</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.573</ArticleId><ArticleId IdType="pmc">PMC8521292</ArticleId><ArticleId IdType="pubmed">34709745</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Syed F, Yu R, Yang J, Xia Y, Relich RF, et al. . Soluble immune checkpoints are dysregulated in COVID-19 and heavy alcohol users with HIV infection. Front Immunol. (2022) 13:833310. doi:Â 10.3389/fimmu.2022.833310</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.833310</ArticleId><ArticleId IdType="pmc">PMC8904355</ArticleId><ArticleId IdType="pubmed">35281051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavel-Tanasa M, Constantinescu D, Cianga CM, Anisie E, Mereuta AI, Tuchilus CG, et al. . Adipokines, and not vitamin D, associate with antibody immune responses following dual BNT162b2 vaccination within individuals younger than 60 years. Front Immunol. (2022) 13:1000006. doi:Â 10.3389/fimmu.2022.1000006</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1000006</ArticleId><ArticleId IdType="pmc">PMC9481237</ArticleId><ArticleId IdType="pubmed">36119038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapsiani S, Howlin BJ. Random forest classification for predicting lifespan-extending chemical compounds. Sci Rep. (2021) 11:13812. doi:Â 10.1038/s41598-021-93070-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-93070-6</ArticleId><ArticleId IdType="pmc">PMC8257600</ArticleId><ArticleId IdType="pubmed">34226569</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Diz S, Marin-Benesiu F, Lopez-Torres G, Santiago O, Diaz-Cuellar JF, Martin-Esteban S, et al. . Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19. Front Immunol. (2022) 13:1094644. doi:Â 10.3389/fimmu.2022.1094644</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1094644</ArticleId><ArticleId IdType="pmc">PMC10031647</ArticleId><ArticleId IdType="pubmed">36969980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman E, Scott AM, Karlsson C, Mohanty T, Vaara ST, Linder A, et al. . Interpreting biologically informed neural networks for enhanced proteomic biomarker discovery and pathway analysis. Nat Commun. (2023) 14:5359. doi:Â 10.1038/s41467-023-41146-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41146-4</ArticleId><ArticleId IdType="pmc">PMC10475049</ArticleId><ArticleId IdType="pubmed">37660105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Beck MW, Winkler DA, Huang B, Sibanda W, Goyal H, et al. . Opening the black box of neural networks: methods for interpreting neural network models in clinical applications. Ann Transl Med. (2018) 6:216. doi:Â 10.21037/atm.2018.05.32</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.05.32</ArticleId><ArticleId IdType="pmc">PMC6035992</ArticleId><ArticleId IdType="pubmed">30023379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Allison JP. The future of immune checkpoint therapy. Science. (2015) 348:56â61. doi:Â 10.1126/science.aaa8172</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8172</ArticleId><ArticleId IdType="pubmed">25838373</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyo JY, Yoon T, Ahn SS, Song JJ, Park YB, Lee SW. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Sci Rep. (2022) 12:21319. doi:Â 10.1038/s41598-022-25466-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-25466-x</ArticleId><ArticleId IdType="pmc">PMC9734661</ArticleId><ArticleId IdType="pubmed">36494415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Lang J. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. (2017) 8:97671â82. doi:Â 10.18632/oncotarget.18311</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.18311</ArticleId><ArticleId IdType="pmc">PMC5722594</ArticleId><ArticleId IdType="pubmed">29228642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol. (1995) 155:4917â25. doi:Â 10.4049/jimmunol.155.10.4917</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.155.10.4917</ArticleId><ArticleId IdType="pubmed">7594496</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol. (2009) 21:265â72. doi:Â 10.1016/j.smim.2009.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2009.05.010</ArticleId><ArticleId IdType="pmc">PMC2749083</ArticleId><ArticleId IdType="pubmed">19524453</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. (2009) 229:152â72. doi:Â 10.1111/j.1600-065X.2009.00782.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2009.00782.x</ArticleId><ArticleId IdType="pmc">PMC3826168</ArticleId><ArticleId IdType="pubmed">19426221</ArticleId></ArticleIdList></Reference><Reference><Citation>Elizondo DM, Andargie TE, Kubhar DS, Gugssa A, Lipscomb MW. CD40-CD40L cross-talk drives fascin expression in dendritic cells for efficient antigen presentation to CD4+ T cells. Int Immunol. (2017) 29:121â31. doi:Â 10.1093/intimm/dxx013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxx013</ArticleId><ArticleId IdType="pmc">PMC5421612</ArticleId><ArticleId IdType="pubmed">28369442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol. (2005) 45:1280â6. doi:Â 10.1016/j.jacc.2004.12.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2004.12.071</ArticleId><ArticleId IdType="pubmed">15837262</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Yang Y, Li Y, Wang Z, Ma F, Luo R, et al. . Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein. J Clin Invest. (2022) 132:e150101. doi:Â 10.1172/JCI150101</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI150101</ArticleId><ArticleId IdType="pmc">PMC8843740</ArticleId><ArticleId IdType="pubmed">34964720</ArticleId></ArticleIdList></Reference><Reference><Citation>Valet C, Magnen M, Qiu L, Cleary SJ, Wang KM, Ranucci S, et al. . Sepsis promotes splenic production of a protective platelet pool with high CD40 ligand expression. J Clin Invest. (2022) 132:e153920. doi:Â 10.1172/JCI153920</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI153920</ArticleId><ArticleId IdType="pmc">PMC8970674</ArticleId><ArticleId IdType="pubmed">35192546</ArticleId></ArticleIdList></Reference><Reference><Citation>Klersy A, Meyer S, Leuschner F, Kessler T, Hecker M, Wagner AH. Ectodomain shedding by ADAM17 increases the release of soluble CD40 from human endothelial cells under pro-inflammatory conditions. Cells. (2023) 12:1926. doi:Â 10.3390/cells12151926</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12151926</ArticleId><ArticleId IdType="pmc">PMC10417149</ArticleId><ArticleId IdType="pubmed">37566005</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer S, Kopp HG, Salih HR, Kropp KN. Modulation of immune responses by platelet-derived ADAM10. Front Immunol. (2020) 11:44. doi:Â 10.3389/fimmu.2020.00044</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00044</ArticleId><ArticleId IdType="pmc">PMC7012935</ArticleId><ArticleId IdType="pubmed">32117229</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima M, Uchimaru K. CD30 expression and its functions during the disease progression of adult T-cell leukemia/lymphoma. Int J Mol Sci. (2023) 24:8731. doi:Â 10.3390/ijms24108731</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24108731</ArticleId><ArticleId IdType="pmc">PMC10218159</ArticleId><ArticleId IdType="pubmed">37240076</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Guo W, Bai O. Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Front Oncol. (2023) 13:1301437. doi:Â 10.3389/fonc.2023.1301437</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2023.1301437</ArticleId><ArticleId IdType="pmc">PMC10767573</ArticleId><ArticleId IdType="pubmed">38188299</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui D, Zhang Y, Chen L, Du H, Zheng B, Huang M, et al. . CD30 plays a role in T-dependent immune response and T cell proliferation. FASEB J. (2024) 38:e23365. doi:Â 10.1096/fj.202301747RR</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202301747RR</ArticleId><ArticleId IdType="pubmed">38069862</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber ML, Oldham RAA, Thakur A, Rademacher MJ, Kubicka E, Dlugi TA, et al. . Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. Front Immunol. (2023) 14:1225610. doi:Â 10.3389/fimmu.2023.1225610</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1225610</ArticleId><ArticleId IdType="pmc">PMC10461807</ArticleId><ArticleId IdType="pubmed">37646042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol. (2003) 12:49â61. doi:Â 10.1016/S0966-3274(03)00014-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-3274(03)00014-5</ArticleId><ArticleId IdType="pubmed">14551032</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzona M, Jack HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol. (1994) 153:2861â7. doi:Â 10.4049/jimmunol.153.7.2861</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.153.7.2861</ArticleId><ArticleId IdType="pubmed">8089475</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspal FM, Kim MY, McConnell FM, Raykundalia C, Bekiaris V, Lane PJ. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory. J Immunol. (2005) 174:3891â6. doi:Â 10.4049/jimmunol.174.7.3891</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.7.3891</ArticleId><ArticleId IdType="pubmed">15778343</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z, Li Q, Wang Y, Gao G, Diggs LS, Tellides G, et al. . CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest. (2004) 113:310â7. doi:Â 10.1172/JCI19727</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI19727</ArticleId><ArticleId IdType="pmc">PMC311434</ArticleId><ArticleId IdType="pubmed">14722622</ArticleId></ArticleIdList></Reference><Reference><Citation>Vick SC, Frutoso M, Mair F, Konecny AJ, Greene E, Wolf CR, et al. . A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. Sci Adv. (2021) 7:eabj0274. doi:Â 10.1126/sciadv.abj0274</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abj0274</ArticleId><ArticleId IdType="pmc">PMC8580318</ArticleId><ArticleId IdType="pubmed">34757794</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Yunis J, Yao Y, Shi J, Yang Y, Zhou P, et al. . High levels of soluble CD25 in COVID-19 severity suggest a divergence between anti-viral and pro-inflammatory T-cell responses. Clin Transl Immunol. (2021) 10:e1251. doi:Â 10.1002/cti2.1251</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1251</ArticleId><ArticleId IdType="pmc">PMC7883478</ArticleId><ArticleId IdType="pubmed">33614032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. (2020) 20:529â36. doi:Â 10.1038/s41577-020-0402-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0402-6</ArticleId><ArticleId IdType="pmc">PMC7389156</ArticleId><ArticleId IdType="pubmed">32728222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. . Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. (2020) 17:541â3. doi:Â 10.1038/s41423-020-0401-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0401-3</ArticleId><ArticleId IdType="pmc">PMC7091621</ArticleId><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki-Hozumi H, Chagan-Yasutan H, Ashino Y, Hattori T. Blood levels of galectin-9, an immuno-regulating molecule, reflect the severity for the acute and chronic infectious diseases. Biomolecules. (2021) 11:430. doi:Â 10.3390/biom11030430</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11030430</ArticleId><ArticleId IdType="pmc">PMC7998537</ArticleId><ArticleId IdType="pubmed">33804076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozorgmehr N, Mashhouri S, Perez Rosero E, Xu L, Shahbaz S, Sligl W, et al. . Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. mBio. (2021) 12:e00384-21. doi:Â 10.1128/mBio.00384-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00384-21</ArticleId><ArticleId IdType="pmc">PMC8262904</ArticleId><ArticleId IdType="pubmed">33947753</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbaz S, Dunsmore G, Koleva P, Xu L, Houston S, Elahi S. Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection. J Immunol. (2020) 204:2474â91. doi:Â 10.4049/jimmunol.1901481</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1901481</ArticleId><ArticleId IdType="pubmed">32205423</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannone N, Liang J, Antonopoulos A, Geddes Sweeney J, King SL, Pochebit SM, et al. . Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans. Nat Commun. (2018) 9:3287. doi:Â 10.1038/s41467-018-05770-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05770-9</ArticleId><ArticleId IdType="pmc">PMC6098069</ArticleId><ArticleId IdType="pubmed">30120234</ArticleId></ArticleIdList></Reference><Reference><Citation>Madireddi S, Eun SY, Lee SW, Nemcovicova I, Mehta AK, Zajonc DM, et al. . Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med. (2014) 211:1433â48. doi:Â 10.1084/jem.20132687</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20132687</ArticleId><ArticleId IdType="pmc">PMC4076583</ArticleId><ArticleId IdType="pubmed">24958847</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, et al. . Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. (2021) 12:832. doi:Â 10.1038/s41467-021-21099-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21099-2</ArticleId><ArticleId IdType="pmc">PMC7864927</ArticleId><ArticleId IdType="pubmed">33547304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, et al. . Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology. (2012) 153:612â20. doi:Â 10.1210/en.2011-1579</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2011-1579</ArticleId><ArticleId IdType="pubmed">22186414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang N, Alimu X, Chen R, Muhashi M, Ma J, Chen G, et al. . Activated Galectin-9/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J. (2021) 35:e21556. doi:Â 10.1096/fj.202100013R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100013R</ArticleId><ArticleId IdType="pubmed">34137463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MA, Andersen T, Etzerodt A, Kragstrup TW, Rasmussen TK, Stengaard-Pedersen K, et al. . A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis. Rheumatol (Oxford). (2016) 55:1871â9. doi:Â 10.1093/rheumatology/kew237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew237</ArticleId><ArticleId IdType="pubmed">27330157</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK. Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol. (2010) 88:1201â5. doi:Â 10.1189/jlb.0410235</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0410235</ArticleId><ArticleId IdType="pubmed">20807704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori Y, Fink C, Ichimura T, Sako K, Mori M, Lee NN, et al. . KIM-1/TIM-1 is a receptor for SARS-CoV-2 in lung and kidney. medRxiv. (2022). doi:Â 10.1101/2020.09.16.20190694</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.16.20190694</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweigert O, Dewitz C, Moller-Hackbarth K, Trad A, Garbers C, Rose-John S, et al. . Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine. Biochim Biophys Acta. (2014) 1843:275â87. doi:Â 10.1016/j.bbamcr.2013.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2013.11.014</ArticleId><ArticleId IdType="pubmed">24286866</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT, Dekruyff RH, et al. . TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood. (2007) 110:2565â8. doi:Â 10.1182/blood-2006-11-058800</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-11-058800</ArticleId><ArticleId IdType="pmc">PMC1988955</ArticleId><ArticleId IdType="pubmed">17620455</ArticleId></ArticleIdList></Reference><Reference><Citation>Bod L, Kye YC, Shi J, Torlai Triglia E, Schnell A, Fessler J, et al. . B-cell-specific checkpoint molecules that regulate anti-tumor immunity. Nature. (2023) 619:348â56. doi:Â 10.1038/s41586-023-06231-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06231-0</ArticleId><ArticleId IdType="pmc">PMC10795478</ArticleId><ArticleId IdType="pubmed">37344597</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiari S, Donnarumma T, Rossi B, Dusi S, Pietronigro E, Zenaro E, et al. . TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. Immunity. (2014) 40:542â53. doi:Â 10.1016/j.immuni.2014.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4066214</ArticleId><ArticleId IdType="pubmed">24703780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. (2008) 123:538â46. doi:Â 10.1111/j.1365-2567.2007.02723.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02723.x</ArticleId><ArticleId IdType="pmc">PMC2433324</ArticleId><ArticleId IdType="pubmed">18194267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. . B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. (2001) 2:269â74. doi:Â 10.1038/85339</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/85339</ArticleId><ArticleId IdType="pubmed">11224528</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. . The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. (2003) 4:899â906. doi:Â 10.1038/ni967</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni967</ArticleId><ArticleId IdType="pubmed">12925852</ArticleId></ArticleIdList></Reference><Reference><Citation>Antohe I, Tanasa MP, Dascalescu A, Danaila C, Titieanu A, Zlei M, et al. . The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukemias blast cells HLA-DR expression. Immunobiology. (2021) 226:152049. doi:Â 10.1016/j.imbio.2020.152049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2020.152049</ArticleId><ArticleId IdType="pubmed">33352400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Liu G, Zhong J, Zheng K, Xiao H, Li C, et al. . Immune checkpoints in viral infections. Viruses. (2020) 12:1051. doi:Â 10.3390/v12091051</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12091051</ArticleId><ArticleId IdType="pmc">PMC7551039</ArticleId><ArticleId IdType="pubmed">32967229</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>